Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.31
FOLD's Cash to Debt is ranked lower than
65% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. FOLD: 4.31 )
Ranked among companies with meaningful Cash to Debt only.
FOLD' s Cash to Debt Range Over the Past 10 Years
Min: 4.31  Med: 50.47 Max: No Debt
Current: 4.31
F-Score: 2
Z-Score: -0.61
M-Score: -2.48
WACC vs ROIC
10.61%
-152.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -51.50
FOLD's ROE (%) is ranked lower than
62% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. FOLD: -51.50 )
Ranked among companies with meaningful ROE (%) only.
FOLD' s ROE (%) Range Over the Past 10 Years
Min: -322.07  Med: -82.09 Max: -9.19
Current: -51.5
-322.07
-9.19
ROA (%) -22.58
FOLD's ROA (%) is ranked higher than
56% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. FOLD: -22.58 )
Ranked among companies with meaningful ROA (%) only.
FOLD' s ROA (%) Range Over the Past 10 Years
Min: -104.95  Med: -44.78 Max: -6.13
Current: -22.58
-104.95
-6.13
ROC (Joel Greenblatt) (%) -3001.67
FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. FOLD: -3001.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FOLD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2904.44  Med: -1385.29 Max: -134.99
Current: -3001.67
-2904.44
-134.99
Revenue Growth (3Y)(%) -100.00
FOLD's Revenue Growth (3Y)(%) is ranked lower than
98% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. FOLD: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FOLD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70.40 Max: -2.3
Current: -100
EBITDA Growth (3Y)(%) 2.00
FOLD's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. FOLD: 2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FOLD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.6  Med: -13.50 Max: 81.7
Current: 2
-85.6
81.7
EPS Growth (3Y)(%) 3.90
FOLD's EPS Growth (3Y)(%) is ranked higher than
61% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. FOLD: 3.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FOLD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.2  Med: -14.20 Max: 54.6
Current: 3.9
-85.2
54.6
» FOLD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

FOLD Guru Trades in Q2 2015

Chuck Royce 380,000 sh (New)
Paul Tudor Jones 106,356 sh (+815.28%)
Steven Cohen 916,700 sh (+427.14%)
Louis Moore Bacon 275,000 sh (+95.53%)
RS Investment Management 2,687,065 sh (+4.78%)
» More
Q3 2015

FOLD Guru Trades in Q3 2015

RS Investment Management 2,860,425 sh (+6.45%)
Steven Cohen Sold Out
Chuck Royce 334,000 sh (-12.11%)
Louis Moore Bacon 125,000 sh (-54.55%)
Paul Tudor Jones 38,735 sh (-63.58%)
» More
Q4 2015

FOLD Guru Trades in Q4 2015

RS Investment Management 3,488,863 sh (+21.97%)
Louis Moore Bacon 125,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 105,300 sh (-68.47%)
» More
Q1 2016

FOLD Guru Trades in Q1 2016

Paul Tudor Jones 16,950 sh (New)
RS Investment Management 3,527,703 sh (+1.11%)
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ANIK, NAS:XNCR, OTCPK:BPMUF, NAS:KERX, NAS:MACK, NAS:PACB, OTCPK:TYMI, NAS:CASC, NAS:INSM, OTCPK:AUCL, NAS:ANIP, OTCPK:CMVLF, NAS:CERS, NAS:INO, NAS:NTLA, OTCPK:GNFTF, NAS:CEMP, NAS:ATRA, OTCPK:IPHYF, NAS:CORT » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines for orphan diseases.

Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone- Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone- Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.

Ratios

vs
industry
vs
history
P/B 2.41
FOLD's P/B is ranked higher than
63% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. FOLD: 2.41 )
Ranked among companies with meaningful P/B only.
FOLD' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 3.28 Max: 14.52
Current: 2.41
0.87
14.52
Current Ratio 2.62
FOLD's Current Ratio is ranked lower than
68% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. FOLD: 2.62 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s Current Ratio Range Over the Past 10 Years
Min: 2.62  Med: 7.66 Max: 21.6
Current: 2.62
2.62
21.6
Quick Ratio 2.62
FOLD's Quick Ratio is ranked lower than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. FOLD: 2.62 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s Quick Ratio Range Over the Past 10 Years
Min: 2.62  Med: 7.66 Max: 21.6
Current: 2.62
2.62
21.6

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -23.50
FOLD's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. FOLD: -23.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FOLD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 46.5  Med: 98.90 Max: 913.7
Current: -23.5
46.5
913.7

More Statistics

EPS (TTM) $ -1.28
Beta1.23
Short Percentage of Float28.94%
52-Week Range $4.98 - 18.83
Shares Outstanding (Mil)127.05
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg as Vice President,... Jul 12 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 11 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Jul 06 2016
Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent... Jul 06 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jul 01 2016
Research Report Initiated on Select Biotechnology Equities Jun 24 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 13 2016
Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors Jun 10 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits Jun 09 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors Jun 09 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 07 2016
Redmile Group Sticking With Healthcare Picks After Rough Q1 Jun 03 2016
5 Breakout Stocks Under $10 Set to Soar Jun 02 2016
Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 Jun 01 2016
Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference Jun 01 2016
Amicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease May 31 2016
Amicus' Fabry disease drug gets European Commission approval May 31 2016
Amicus' Fabry disease drug gets European Commission approval May 31 2016
Amicus' Fabry disease drug gets European Commission approval May 31 2016
Amicus Therapeutics Announces European Commission Approval for Galafold™ (Migalastat) in Patients... May 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)